Fresh human sera neutralize Friend leukaemia virus (FLV). The activity is abolished by heating (56 °C for 30 min), hydrazine and EDTA treatment, suggesting the involvement of complement. Human sera also contain antibody which specifically reacts with FLV. Following incubation with human whole serum, IgG and F(ab')~ fragments, FLV acquire the ability to bind anti-human Ig sera, as shown in neutralization and radioimmunoprecipitation assays. The same is true for FLV-infected cells but not for uninfected control cells, as assessed by immunofluorescence. The binding of antibody to FLV-infected cells is prevented by pre-treating the cells with antisera to FLV and FLV-gp7I, and is competed by FLV, FLV-gp7I and, to a lesser extent, by FLV-pI2 and p3o.
INTRODUCTION
There have been several reports on the presence of antibody to mammalian type-C oncovirus in humans. Positive results have repeatedly been described by using as test antigens primate viruses or various purified structural proteins extracted from them (Lewis et al. I974; Kim, I975; Aoki et al. I976a; Louie et al. I976; Prochownik & Kirsten, 1976; Snyder et al. 1976; Kurth et al. I977; Hirsch et al. I978; Jacquemin et al. 1978; Thiry et al. 1978; Witkin et al. 1978) . Less consistent results have been obtained when viruses or virus antigens from lower animals were employed; reactivities attributable to antibody have been detected by some investigations in the serum (Fink et al. I964; Hersh et al. I974; Olsen & Yohn I974; Snyder et al. 1976; Kurth et al. I977; Simkovic et al. I977; Jacquemin et al. 1978; Kurth & Mikschy, 1978) and kidney eluates (Mellors & Mellors, I978) but not by others (Charman et al. 1974; Stephenson & Aaronson, 1976; Krakower & Aaronson, 1978) . Moreover, positive reactivities were generally slight and present in a low proportion of subjects. Factors in human sera which inactivate type-C viruses have also been described, but were either not characterized (Bendinelli et al. I974) or recognized as not involving antibody (Fieldsteel, I974; Cooper et al. 1976; Bartholomew et al. I978; Sherwin et al. 1978) .
In this paper we show that sera from healthy humans consistently contain antibodies which bind to Friend leukaemia virus (FLV) complex and are mainly directed towards antigenic determinants on its major envelope glycoprotein, gPTI. 
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Angeles, Calif., U.S.A.). Polyspecific rabbit anti-mouse Ig (Ra. a. Molg) was purchased from Meloy Lab (Springfield, Va., U.S.A.). Hyperimmune anti-FLV serum and monospecific antisera against purified FLV-gp7I, -p3o or -pr2 proteins were raised in goats (generous gifts of Dr D. Bolognesi, Durham, North Carolina) and absorbed on DBA/2 mouse spleen, kidney and liver cells at 4 °C for 2 h before use. Mouse anti-FLV serum was raised in BALB/c mice by repeated injections of a formalinized FLV-infected spleen cell extract in Freund's complete adjuvant. Absorption of human sera. FLC or 5-to 8-day old primary cultures of bone marrow cells from uninfected DBA/2 mice were collected by centrifugation. Spleen, liver and kidney cells were obtained from previously exsanguinated young adult DBA/2 mice. Sheep red blood cells (SRBC), human red blood cells (HRBC), and mouse red blood cells (MRBC) were obtained from Sclavo (Siena, Italy) suspended in Alsever's solution. All cells were washed a minimum of three times in phosphate buffered saline (PBS), pH 7"3, before use. Absorptions were carried out by incubating 0"5 ml of serum diluted I : 1o in PBS with either red cells (8 × roS), nucleated ceils (5 x ios to 5 x Io7), FLV or purified FLV proteins at 37 °C for 30 rain and at 4 °C for 2 h. After centrifugation at 3oo0 g, the supernatant was immediately assayed. Mock absorptions were done identically but without using cells, virus or proteins.
Virus neutralization tests. Three methods were used. Spleen weight assay. FLV diluted in PBS to contain Ioo IDs0 in o.I ml was incubated with an equal volume of twofold dilutions of the serum under test at 37 °C for 45 min with occasional shaking. Controls with heat-inactivated serum (56 °C for 3 o min) and PBS were always run in parallel. The mixtures were then injected into lots of 3 to 5 BALB/c mice (o.2 ml intravenously) and 3 weeks later the mice were killed and the spleens weighed. The highest dilution of serum which reduced the spleen weight by 5o ~o or more was taken as the neutralizing titre.
S+L -cell assay. FLV diluted to contain IOO (S+L -) f.f.u, in o-2 ml was incubated with serum as in the previous assay. The mixtures (o'4 ml) were then inoculated on to two Falcon plastic dishes (6 cm in diam.) plated the day before with i .6 × IO 5 S+L -D56 cells (Bassin et al. I97I) in 4 m! of McCoy's 5 A medium supplemented with Io% heat-inactivated (at 56 °C for 30 min) FCS and pre-treated with 25/zg/ml DEAE-dextran for 20 rain before inoculation. The culture medium was replaced 2 days later and the cells were stained with Amido black after an additional 2-day incubation. Foci of transformed cells were counted at low magnification. The highest dilution of serum which reduced the number of foci by 5o % or more was taken as the neutralizing titre.
XC cell assay. FLV diluted to contain IOO (XC) p.f.u, in o.2 ml was incubated with serum as above. The mixtures (o'4 ml) were then inoculated on to subconfluent SC-I cells in Falcon dishes (6 cm in diam.) plated the day before and pre-treated with DEAEdextran as above. Three days later the cells were irradiated with 5ooo rads (cobalt) and super-seeded with I × Io 6 XC cells in 4 ml medium (Rowe et al. I97O). The culture medium was replaced 2 days later and the cells were stained with Amido black after an additional 2-day incubation. The highest dilution of serum which reduced the number of plaques by 5o 0/0 or more was taken as the neutralizing titre.
Radioimrnunoprecipitation (RIP) assay against intact FLV. The method adopted was similar to that described by Ihle et al. (I974) . Twofold dilutions of the serum under test (200/~1) were made from an initial I : Io dilution in tris-HC1, 0.02 M, pH 7"6, in o.I M-NaCIo.oot M-EDTA (TNE-A) buffer. SH-labelled intact FLV was then added (20 #1 vol., 5000 to 22 ooo ct/min/2o ng protein) to each dilution. After incubation at 37 °C for I h and at 4 °C for another hour, all the IgG in each dilution was precipitated by adding 20/~1 of an appropriate dilution of G. a. HuIg serum in TNE-A. The mixtures were incubated at 37 °C for I h and at 4 °C for 4 h, and then precipitated at 3000 g for 20 min. After two washings in TNE-A, the pellets were dissolved in 1-o M-NaOH and IOO/~l samples were transferred into scintillation vials containing 5 ml Aquasol (New England Nuclear Corp.) and counted. Reactivity was expressed as the percentage of added radioactive virus present in the precipitate. In certain cases, the highest dilution of serum which precipitated 5o % or more of the added TCA-precipitable radioactivity was taken as the RIP titre.
RIP assay against purified FL V proteins. Purified virus gp7I and p3o and p I2 from FLVinfected 745 cells were prepared as described by Green et al. (1973) Moennig et al. (1973) and Schafer et al. (I975) . Some preparations of gp71 and p3o from FLV-Eveline-STU cells were a generous gift of Dr D. Bolognesi. Proteins were labelled by the chloramine-T procedure and the RIP assays were performed essentially as described previously (Strand et al. I974) . The reaction mixture consisted of: (I) 5o/4 of serum diluted in TNE-B buffer (TNE-A buffer supplemented with bovine serum albumin, IO mg/ml) containing o'5% NP4o and o-oI M-NaI; (2) Io#l of 125I-labelled virus protein (5 ng, approx. 2 to 5 x io 4 TCA precipitable ct/min) in 4oo #1 plastic Beckman tubes. After incubation for 16 h at 4 °C, 2o/zl of an appropriate dilution of G. a. HuIg serum in TNE-B were added to the mixtures. After additional incubation for I h at 37 °C and I h at 4 °C, the precipitate was pelleted for 3 min in a Beckman microfuge, washed twice in TNE-A supplemented,with o'5 o/o NP4o and tested for the presence of lzSI-labelled antigen in an autogamma LKB spectrometer.
Competitive RIP assay. Intact FLV or purified gP7I, p3o and pI5 at varying concentrations, were used as inhibitors of the binding reaction of an optimally labelled FLV-or FLV protein-test serum (or specific antiserum) combination. Test sera were generally used at four times the concentration which precipitated 5o % of the labelled antigen. Reactivity was expressed as the percentage of labelled antigen precipitated by the same serum dilution in the absence of inhibitors.
Immunofluoreseenee (IF) . The indirect live cell membrane or, alternatively the acetonefixed cell IF assay was used as previously described (Cloyd et al. I977) . Briefly, thoroughly washed cells were incubated for I h at 37 °C with various dilutions of primary sera, washed three times in PBS and incubated with fluoresceinated secondary antiserum which had been previously absorbed for 2 h at 4 °C on 745 cells and on BALB/c or DBA/2 mouse kidney, spleen and liver cells to prevent non-specific staining. The anti-FLV specificity of the human serum binding to cells was studied by blocking experiments: these were performed by pretreating the target cells for I h with candidate blocking serum. At least 5oo cells were scored for fluorescence under dark field u.v. illumination with a Zeiss Universal microscope.
RESULTS

FL V neutralization
As shown by Table I , the FLV neutralizing activity of pooled fresh human serum was detected by both in vivo and in vitro tests, but the latter were more sensitive. The in vitro S+L -and XC tests exhibited superimposable sensitivities but, due to its simplicity, the former was used in subsequent experiments.
All the individual fresh sera tested, from healthy adults, children or newborns, neutralized FLV (Table 2 ). There was considerable variability in the activity of individual sera, but on average, adult sera were somewhat more active than infant or newborn sera. Representative titration curves by individual sera are presented in Fig. I ; most sera gave linear curves indicating that there was no non-neutralizable virus fraction. Other experiments (data not presented) showed that neutralization required direct contact between serum and virus (pre- incubation of S+L -cells with serum followed by three washings prior to FLV inoculation or addition of serum to the cultures 2 h after infection had no detectable effect on focus formation) and that there was no detectable difference in susceptibility to neutralization between FLV-A and FLV-P, whether harvested from mice or from tissue cultures. The neutralizing activity was nearly completely abolished by treatment of sera at 56 °C for 30 min (Table I) or with hydrazine, or by the presence of EDTA in the neutralization mixture but was little affected by prior heating of the serum at 5 °C for 25 min (Table 3) . :1: Fresh serum was supplemented with an equal vol. of o'I M-Na2 EDTA in o"5 u-tris-HCl, pH 7"3, and diluted in Ca-and Mg-free PBS. At the end of incubation, the neutralization mixtures were chilled and supplemented with appropriate dilutions of cold o" 15 M-CaCI~ at the moment of inoculation.
§ Fresh serum was supplemented with a half vol. of 0.2 ~-Naa EDTA and half vol. of 0'3 M-CaCI2 and diluted in Ca-and Mg-free PBS. Table 3. t After the 1st incubation the mixtures were supplemented with an equal vol. of the indicated reagent, incubated for additional 20 rain and then centrifuged in the cold at 700 g for zo min. Before use the antisera were treated with hydrazine and diluted I : IO.
:~ Pool of IO adult sera. Table 4 presents the results of experiments in which FLV was first incubated with hydrazine-decomplemented human serum and then incubated for one further hour in the presence of anti-human whole serum or of monospecific anti-human Ig antisera (also decomplemented with hydrazine). Decomplemented human serum, as expected, neutralized little FLV infectivity but rendered it neutralizable by (in order of effectiveness) Ra. a. HulgG and Ra.a. HuS serum. G.a. HulgM serum afforded some neutralization of both human serum-sensitized and unsensitized virus. G.a. HulgA serum and control rabbit serum did not neutralize sensitized FLV. 
RIP of intact FL V and purified FL V proteins
Human sera were analysed for intact FLV-binding Ig by means of a sensitive and specific RIP assay. All the sera tested exhibited a significant though variable binding (representative results shown in Fig. za) . The average RIP titre of sera from healthy adult donors was about I:ZOO and that of children, whether healthy or carriers of neuroblastomas, and of newborns was not much lower. Only the few tested sera from patients with hypogammaglobulinaemia or ALL had lower binding activity. There was no apparent correlation between neutralization and RIP titres ( The Ig nature of the human serum factor(s) binding intact FLV was confirmed by controls showing that: (I) the RIP titre was not lowered by heating the sera at 56 °C for I h (Fig.  2b) ; (2) the binding was almost completely abolished by removal of IgG from the sera by affinity column chromatography (data not shown); (3) solutions of purified IgG and of the derived F(ab')2 at the concentration found in the whole serum presented RIP titres and titration curves similar to those of the original serum (Fig. 2b) .
Whether the human Ig binding was specifically directed to FLV antigens was checked by absorption experiments. The binding power of pooled sera and of randomly chosen sera was not affected by absorption with MRBC, SRBC and HRBC nor was it significantly reduced by absorption with 6-day cultured bone marrow cells from uninfected DBA/2 mice (Fig. 2b) . It was, instead, abolished by absorption with FLV, both of A or P strain whether obtained from infected DBA/z mice or from FLC cultures (Fig. 2 b) . FLC clones 745 and 3BM-78-o35, were somewhat more active in removing the binding activity of human serum than clone F4-l, which produces virions lacking the internal p3o protein, as judged on the cell numbers needed for an efficient absorption, but the difference was slight (Fig. 3) . Attempts to identify the molecular nature of the FLV antigens recognized by human Ig were made by RIP assays with purified FLV proteins and by RIP competition experiments. The first approach showed that human serum precipitated 5 ng of FLV-gp7r as effectively as 5o ng of intact FLV and that FLV-p3o was also precipitated but was much less active (Fig. 4a) . In the second approach, the precipitation of labelled intact FLV was competed by 5 ng of FLV-gp7~ as effectively as by 50 ng of cold intact FLV, by FLV-pr2 to a much lower extent and by FLV-p3o with intermediate efficiency (Fig. 4b) .
IF with FL V-infected spleen cells and FLC
The reactivity of pooled human serum with spleen cells was analysed by indirect membrane IF using cells from normal or 2I-day FLV-infected BALB/c mice. The results (summarized in Table 6 ) showed that, as detected by fluoresceinated Ra.a. HuIg serum, human sera bound to FLV-infected spleen cells but not to normal spleen cells. The specificity for FLV antigen(s) of the human Ig reactivity was confirmed by blocking experiments: human serum reactivity was totally and specifically blocked by pre-incubation of the target FLV-infected cells with syngeneic mouse anti-FLV serum and vice versa.
Indirect IF with FLC (clone 3BM-78-o35) was done with both live and fixed cells. Either method showed that not only human whole sera (usually at ~ : zo dilution), but also purified human Ig and F(ab')2 pepsin-fragments bound to FLC (data not shown). On the fixed cells fluorescence appeared on the membrane and in the entire cytoplasm. The reactivity could be inhibited by pre-incubating FLC with goat anti-FLV-gp7I serum (dilution I:5o) as well as by submitting the human serum in test to depletion of IgG and to a lower extent of IgM by means of affinity columns (Fig. 5) , and to pre-incubation with 5o #g FLV or 5 ng FLV-gp7I (Fig. 6) . Moreover 8o % of the sera tested blocked the capacity of flu oresceinated goat anti-FLV antibody to react with live or fixed FLC. This blocking capacity was almost completely removed by pre-exposure to 5 ng purified FLV-gp7l in J8 out of 2o sera tested. As a control for the FLV-specificity of the human serum binding, human sera were also reacted with 6-day primary cultures of bone marrow cells from DBA/2 mice: only 3 out of 35 sera tested (diluted t:5) stained these cells and their reactivity was totally blocked by pre-incubation with 5 ng of purified FLV-gp7I.
DISCUSSION
It was previously shown that fresh human sera can neutralize FLV infectivity (Bendinelli et al. I974) . In the present studies this property of human serum, by analogy with the similar property of guinea pig serum (Bendinelli et al. 1974) and with the retrovirus lyric action of human serum (Cooper et al. I976; Bartholomew et aL 1978; Sherwin et al. 1978) , proved strongly dependent on a normal functioning of the classical complement pathway, as indicated by its almost complete removal following decomplementation by heat or hydrazine, by its marked reduction when divalent cations in the reaction mixture were chelated with EDTA and by its nearly total resistance to a heat treatment (5o °C for 25 min) known to destroy properdin factor B.
However, the finding that a portion of the neutralizing power consistently resisted serum decomplementation suggested that additional factor(s) might be involved. Natural antibody was an obvious candidate. This possibility was substantiated by the observation that FLV, infected spleen cells or cell lines and purified FLV proteins, following incubation with human sera, acquire the ability to bind anti-human Ig sera in a fashion detectable in neutrali- not neutralized by anti-human IgG serum; (ii) in the RIP test against intact FLV, as well as in the IF assays, purified IgG and the corresponding F(ab')~ fragments at the concentration present in whole serum were as active as the unfractionated original serum; (iii) specific removal of IgG from human sera also removed their ability to react with FLV and FLC.
Our present results also provide strong evidence that the antigen(s) recognized by human IgG which react to FLV are viral in nature and the facts which led to this conclusion were: (i) human sera reacted equally well with the anaemia-and the polycythaemia-inducing strains of FLV, whether grown in vivo or in cultured cells; (ii) in IF, human sera reacted strongly with FLV-infected cells, whether producers of complete or of p3o-defective virus, but did not react or reacted very weakly, with uninfected control cells and the reaction could be inhibited by prior incubation of the test cells with homologous or heterologous antibody to FLV. Holder et aL (r976) have described that uninfected mouse cell cultures express low levels of retrovirus glycoprotein antigens on the cell membrane. The occasional reactivity of human sera with uninfected mouse bone marrow cells could be explained in accordance with these findings: (iii) in neither the RIP nor in the IF assay was the level of reactivity between human sera and FLV influenced by performing the tests in the presence of FCS, which can be found linked to in vitro propagated retroviruses (Snyder & Fox, I978) ; (iv) the reactivity of human sera, as studied in RIP and IF, was entirely absorbed by purified FLV and by FLC, but not by appropriate control mouse cells and could be blocked with purified FLV-gp7I ; (v) in RIP assays against purified FLV proteins, human sera reacted strongly with gp71, less with P3O and very poorly with pI2.
It is reasonable to suppose that the natural antibody, unequivocally demonstrated by the present results, is responsible for the low FLV-neutralizing power ofdecomplemented human sera. However, this point is not clarified by the present studies which also do not cast light on its role in the neutralizing activity of fresh serum. In the series of individual sera tested comparatively there was no strict correlation between FLV-neutralizing and RIP titres. For example, sera from hypogammaglobulinaemic patients effectively inhibited FLV but presented low RIP titres. It appears possible that natural antibody contributes only a fraction of the total neutralizing activity of fresh serum, the bulk of which might be due to complement that, according to recent reports ( 
